SCHEMBL4060790

SCHEMBL4060790

CCOC(=O)c1nocc1C(=O)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.46
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
MAPT P10636 1/20 0.46
CASP3 P42574 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
ALDH1A1 P00352 5/20 0.45
NPSR1 Q6W5P4 2/20 0.45
KDM4E B2RXH2 5/20 0.44
LMNA P02545 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
CHRNA7 P36544 1/20 0.41
PTGS2 P35354 2/20 0.41
HTT P42858 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5750757 0.86 ALDH1A1 (0.53) ELANEKMT2AMEN1ALDH1A1NPSR1
SCHEMBL4054635 0.85 ELANE (0.51) ELANEMAPTALDH1A1NPSR1KDM4E
SCHEMBL4050518 0.80 POLB (0.52) ELANEALDH1A1NPSR1NPC1RAB9A
SCHEMBL27654721 0.79 PTGS2 (0.43) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL9586704 0.78 LMNA (0.49) ELANEKMT2AMEN1MAPTALDH1A1
SCHEMBL3033421 0.77 HTT (0.58) ELANEKMT2AMEN1MAPTCASP3
SCHEMBL7948540 0.77 GAA (0.42) ELANEALDH1A1KDM4ENPC1HPGD
SCHEMBL1776614 0.76 KDM4E (0.51) KMT2AMEN1MAPTALDH1A1NPSR1
SCHEMBL18605534 0.74 ALDH1A1 (0.47) ELANEKMT2AMEN1MAPTCASP3
SCHEMBL30487844 0.73 TSHR (0.43) ELANEKMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511038-B2 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors LABORATORIOS ALMIRALL S.A. (ES) 2009-03-31 US disclosed
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-23 US disclosed
EP-1682519-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2006-07-26 EP disclosed
WO-2005049581-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL PRODESFARMA, S.A. (ES) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197536-A1 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease PDE12, PDE4A, PDE7A ELANE 352/4885KMT2A 1928/4885MEN1 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.